Spark and Pfizer’s haemophilia gene therapy gets European PRIME status
Decision based on promising data from ongoing phase 1/2 trial.
X
Spark and Pfizer’s haemophilia gene therapy gets European PRIME status
https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-gene-therapy-gets-priority-medicines-access/
